FlashDx

Join us at MEDICA 2024 in Düsseldorf, Germany from November 11th to 14th, as we showcase our innovative sample-to-answer molecular syndromic testing solutions.

Learn more about our proprietary sSPRT™ technology and discover upcoming product launches that are advancing near-patient diagnostics.

Visit us at booth Hall 3, H26, or contact at [email protected] for product info and to schedule in person meetings at the booth.

We look forward to seeing you there! 🎉

Human metapneumovirus (HMPV) is a common respiratory pathogen that can cause upper and lower respiratory tract infections, particularly in vulnerable populations. While there is currently no effective cure, supportive care can alleviate symptoms and promote recovery. The increased availability of molecular diagnostic testing is enhancing awareness and understanding of HMPV.

www.linkedin.com

Prompt diagnosis and treatment are crucial for effective management of mycoplasma pneumoniae infections. The FlashDX RP1.1 kit, a rapid respiratory pathogen detection tool, can simultaneously detect ten common respiratory pathogens, including mycoplasma pneumoniae, within approximately one hour. This rapid and user-friendly testing approach can facilitate timely diagnosis and appropriate treatment, enhancing patient care.

www.linkedin.com

FlashDx Inc unveils next generation Sample-to-Answer Systems and expands test menu FlashDx introduces the SPRT™ 4T/8T/12T Sample-to-Answer Molecular Test Systems, offering flexible multi-slot capabilities for up to 12 simultaneous tests. Additionally, the company expands its test menu to include Respiratory, Sexually Transmitted Infections, and GBS panels. This expansion further...

We are pleased to announce that our fast molecular POCT solution FlashDx-1000-E will be displayed at MEDLAB MIDDLE EAST 2023! Welcome to join our partners' booth K21 by Neo-Science and F20 by Volta Diagnostic Italy to witness the innovative technologies!

Dear Partners and friends, Dusseldorf 2022 is coming, brings the latest fast Diagnostics Platform to the show. Warmly welcome to meet with us at booth -4.

Synlab's Evaluation of the Point of Care FlashDx system in the detection of SARS-CoV-2, Influenza A/B and RSV

FlashDx's platform got recommendation by SYNLAB to detect the main pathogens of respiratory tract infections Congress of ANL, Akbufeira, Portagal



SYNLAB tested 47 nasopharyngeal swab samples along with 3 external positive quality controls in parallel on FlashDx’s POC system as well as traditional qPCR with automated nucleic acid extraction system. The two methods have 100% concordance rate on the 47 clinical samples and 3 influenza B positive controls. No cross reactions were detected in the tests. The scientists also found the amplification curves are very easy to interpret.

SYNLAB Pathology Molecular Lisbon does recommend FlashDx-1000-E (the instrument) and FlashDx SARS-CoV-2/FluA/FluB/RSVTest, as they present an excellent performance for all analyzed parameters, are very easy to use, output results within 1 hour and allow simultaneous molecular detection of major seasonal respiratory viruses.

FlashDx: Point-of-Care (POC) Multiplex Molecular Diagnostic System FDx-1000 Obtained NMPA Class III Medical Device Registration Certificate

FDx-1000, the proprietary product developed by FlashDx has recently secured China National Medical Products Administration (NMPA, aka China FDA) approval with Class III medical device registration certificate. The corresponding version of FlashDx-1000-E for overseas launch has also obtained EU CE-IVDR certification.

FDx-1000 is a fully automated POC (Point-of-Care) multiplex nucleic acid detection equipment that integrates nucleic acid extraction, amplification, and detection with "sample-in and result-out". Using fully enclosed cartridges with pre-loaded reagents, users only need to add samples with about 1 minute hand-on time. The multiplex real-time quantitative nucleic acid detection can be completed in as little as 40 minutes anytime, anywhere.

Powered by proprietary Microarray-qPCR technologies developed by FlashDx, FDx-1000 provides the sensitivity and specificity comparable to traditional TaqMan qPCR technology and performs highly multiplex nucleic acid detection with single channel fluorescence in a one-pot reaction. It truly offers end users simple, affordable solutions for instant multiplex molecular diagnostics.

Founded by seasoned industry experts across the globe, FlashDx provides turn-key Point-of-Care Molecular test solutions that can be widely applied to hospitals, clinics and physician’s offices. Since its establishment in 2018, the company has developed its IP portfolio and built a 2,500-square-meter R&D laboratory and GMP production plant. The company has also received several rounds of financing from well-known institutions such as Fosun Capital, Zhejiang United Investment Group ("ZUIG"), Yuanbio Venture Capital, and etc. FlashDx’s proprietary Microarray-qPCR technology, combined with the low-cost microfluidic design, enables a highly-multiplex (20-plex or more) quantitative nucleic acid detection from sample to answer in as little as 40 minutes.

Keen on its vision of providing “Affordable Accurate Access” of molecular diagnostics to everyone, FlashDx is dedicated to applying the platform with a growing test menu with its initial focus on syndromic testing in the infectious disease area. The portfolio will expand to oncology and other applications such animal health, identification testing, environment monitoring and food/drug safety etc. FlashDx is OPEN to collaborations at all levels to develop various applications based on its platform.